Analysts Set Expectations for ZNTL Q1 Earnings

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Research analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for Zentalis Pharmaceuticals in a report released on Tuesday, November 11th. HC Wainwright analyst A. Maldonado anticipates that the company will post earnings of ($0.39) per share for the quarter. HC Wainwright has a “Strong-Buy” rating on the stock. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Zentalis Pharmaceuticals’ Q2 2026 earnings at ($0.42) EPS, Q3 2026 earnings at ($0.45) EPS and Q4 2026 earnings at ($0.49) EPS.

A number of other research firms also recently issued reports on ZNTL. Wedbush reissued a “neutral” rating and issued a $4.00 price target on shares of Zentalis Pharmaceuticals in a research note on Tuesday. Wells Fargo & Company cut their target price on Zentalis Pharmaceuticals from $6.00 to $5.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 7th. Leerink Partners restated a “market perform” rating and set a $2.00 price target on shares of Zentalis Pharmaceuticals in a research report on Tuesday. Wall Street Zen downgraded Zentalis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Zentalis Pharmaceuticals in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $5.20.

Zentalis Pharmaceuticals Trading Up 6.1%

Shares of ZNTL opened at $1.40 on Wednesday. The firm has a market cap of $101.00 million, a P/E ratio of -0.68 and a beta of 1.87. The company’s 50-day moving average price is $1.54 and its 200 day moving average price is $1.45. Zentalis Pharmaceuticals has a 12-month low of $1.01 and a 12-month high of $4.44.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings results on Monday, November 10th. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.12.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Catalyst Funds Management Pty Ltd acquired a new stake in Zentalis Pharmaceuticals in the second quarter valued at $31,000. Cerity Partners LLC boosted its position in shares of Zentalis Pharmaceuticals by 58.7% during the 1st quarter. Cerity Partners LLC now owns 20,501 shares of the company’s stock worth $33,000 after acquiring an additional 7,579 shares in the last quarter. Qube Research & Technologies Ltd purchased a new position in shares of Zentalis Pharmaceuticals in the 2nd quarter valued at about $37,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of Zentalis Pharmaceuticals during the 2nd quarter worth about $38,000. Finally, Corient Private Wealth LLC purchased a new stake in Zentalis Pharmaceuticals during the second quarter worth approximately $41,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.